# A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

> **NCT01436864** · PHASE3 · COMPLETED · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 125 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** Recombinant Human VEGF Receptor-Fc Fusion Protein

## Key facts

- **NCT ID:** NCT01436864
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-12
- **Final completion:** 2013-11
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01436864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01436864, "A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01436864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*